Monoclonal Antibodies for the Treatment of Hypercholesterolemia: Targeting PCSK9

Canadian Journal of Cardiology

Volumn 32, Issue 12, 2016, Pages 1552-1560

  Alkindi, Manal ^a   Siminovitch, Katherine A ^b   Gupta, Milan ^c   Genest, Jacques ^a  

^a RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME; ENZYME INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MONOCLONAL ANTIBODY; NEW DRUG; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 INHIBITOR; UNCLASSIFIED DRUG; HYPOCHOLESTEROLEMIC AGENT; PCSK9 PROTEIN, HUMAN; PROPROTEIN CONVERTASE 9;

ARTHRALGIA; BRAIN ISCHEMIA; CARDIOTOXICITY; CLINICAL PRACTICE; CLINICAL TRIAL; CONFUSION; DRUG EFFICACY; DRUG SAFETY; DRUG USE; ENDOCYTOSIS; FAMILIAL HYPERCHOLESTEROLEMIA; FATIGUE; HEADACHE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERSENSITIVITY; INJECTION SITE REACTION; LIMB PAIN; MEMORY DISORDER; NONHUMAN; REVIEW; SKIN TOXICITY; TRANSIENT ISCHEMIC ATTACK; UNSTABLE ANGINA PECTORIS; ANTAGONISTS AND INHIBITORS; DRUG CONTROL; METABOLISM; MOLECULARLY TARGETED THERAPY; PRACTICE GUIDELINE; PROCEDURES; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; DRUG AND NARCOTIC CONTROL; HUMANS; HYPERCHOLESTEROLEMIA; MOLECULAR TARGETED THERAPY; PRACTICE GUIDELINES AS TOPIC; PROPROTEIN CONVERTASE 9; TREATMENT OUTCOME;

EID: 84981717409     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2016.04.013     Document Type: Review

References (47)

1. 1 Winau, F., Westphal, O., Winau, R., Paul Ehrlich—in search of the magic bullet. Microbes Infect 6 (2004), 786–789.
2. 2 “The Nobel Prize in Physiology or Medicine 1908—Award Ceremony Speech.” Nobel Media AB, 2014. Available at https://www.nobelprize.org/nobel_organizations/nobelmedia/. Accessed March 9, 2016.
3. 3 Simon, H.G., 100 Great Operas and Their Stories: Act-by-Act Synopses. 1989, Anchor Books, New York.
4. 4 Foltz, I.N., Karow, M., Wasserman, S.M., Evolution and emergence of therapeutic monoclonal antibodies: what cardiologists need to know. Circulation 127 (2013), 2222–2230.
5. 5 IMS Health data -mra, total prescription numbers and total sales from April 2014 through March 2015. Available at: https://knoema.com/IMSH2014/ims-health-top-line-market-data-2014?global-market=1000090-remicade. Accessed July 1, 2016.
6. 6 Lacouture, M.E., Mechanisms of cutaneous toxicities to EGFR inhibitors. Nature Rev Cancer 6 (2006), 803–812.
7. 7 Hwang, W.Y., Foote, J., Immunogenicity of engineered antibodies. Methods 36 (2005), 3–10.
8. 8 Nelson, A.L., Dhimolea, E., Reichert, J.M., Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 9 (2010), 767–774.
9. 9 Krieckaert, C.L., Nurmohamed, M.T., Wolbink, G.J., Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis 71 (2012), 1914–1915.
10. 10 Goldstein, J.L., Brown, M.S., A century of cholesterol and coronaries: from plaques to genes to statins. Cell 161 (2015), 161–172.
11. 11 Hobbs, H.H., Russell, D.W., Brown, M.S., Goldstein, J.L., The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein. Annu Rev Genet 24 (1990), 133–170.
12. 12 Khera AV, Won HH, Peloso GM, et al. Diagnostic yield of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. J Am Coll Cardiol 2016;67:2578-89.
13. 13 Innerarity, T.L., Mahley, R.W., Weisgraber, K.H., et al. Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia. J Lipid Res 31 (1990), 1337–1349.
14. 14 Abifadel, M., Varret, M., Rabès, J.P., et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 34 (2003), 154–156.
15. 15 Humphries, S.E., Whittall, R.A., Hubbart, C.S., et al. Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk. J Med Genet 43 (2006), 943–949.
16. 16 Tosi, I., Toledo-Leiva, P., Neuwirth, C., Naoumova, R.P., Soutar, A.K., Genetic defects causing familial hypercholesterolaemia: identification of deletions and duplications in the LDL-receptor gene and summary of all mutations found in patients attending the Hammersmith Hospital Lipid Clinic. Atherosclerosis 194 (2007), 102–111.
17. 17 Learning about familial hypercholesterolemia. National Human Genome Research Institute. Available at www.genome.gov/25520184. Accessed May 1, 2016.
18. 18 Marduel, M., Ouguerram, K., Serre, V., et al. Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation. Hum Mutat 34 (2013), 83–87.
19. 19 Awan, Z., Choi, H.Y., Stitziel, N., et al. APOE p.Leu167del mutation in familial hypercholesterolemia. Atherosclerosis 231 (2013), 218–222.
20. 20 Fouchier, S.W., Dallinga-Thie, G.M., Meijers, J.C., et al. Mutations in STAP1 are associated with autosomal dominant hypercholesterolemia. Circ Res 115 (2014), 552–555.
21. 21 Arca, M., Zuliani, G., Wilund, K., et al. Autosomal recessive hypercholesterolemia in Sardinia, Italy, and mutations in ARH: a clinical and molecular genetic analysis. Lancet 359 (2001), 841–847.
22. 22 Stitziel, N.O., Fouchier, S.W., Sjouke, B., et al. Exome sequencing and directed clinical phenotyping diagnose cholesterol ester storage disease presenting as autosomal recessive hypercholesterolemia. Arterioscler Thromb Vasc Biol 33 (2013), 2909–2914.
23. 23 Nordestgaard, B.G., Chapman, M.J., Humphries, S.E., et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 34 (2013), 3478–3490a.
24. 24 Moorjani, S., Roy, M., Torres, A., et al. Mutations of low-density-lipoprotein-receptor gene, variation in plasma cholesterol, and expression of coronary heart disease in homozygous familial hypercholesterolaemia. Lancet 341 (1993), 1303–1306.
25. 25 Raal, F.J., Honarpour, N., Blom, D.J., et al. Inhibition of PCSK9 with evolocumab (AMG 145) in homozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 385 (2015), 331–340.
26. 26 Genest, J., Hegele, R.A., Bergeron, J., et al. Canadian Cardiovascular Society position statement on familial hypercholesterolemia. Can J Cardiol 30 (2014), 1471–1481.
27. 27 Benn, M., Watts, G.F., Tybjærg-Hansen, A., et al. Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217. Eur Heart J 37 (2016), 1384–1394.
28. 28 De Ferrati, S., Rodday, A.M., Mendelson, M., et al. The prevalence of familial hypercholesterolemia in the 1999-2012 United States National Health and Nutrition Examination Survey (NHANES). Circulation 133 (2016), 1067–1072.
29. 29 Talmud, P.J., Shah, S., Whittall, R., et al. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet 381 (2013), 1293–1301.
30. 30 Thompsen, J., Thompson, P.D., A systematic review of LDL apheresis in the treatment of cardiovascular disease. Atherosclerosis 189 (2006), 31–38.
31. 31 Cuchel, M., Meagher, E.A., du Toit Theron, H., et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 381:9860 (2013), 40–46.
32. 32 Rader, D.J., Kastelein, J.J., Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Circulation 129 (2014), 1022–1032.
33. 33 Seidah, N.G., Benjannet, S., Wickham, L., et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A 100 (2003), 928–933.
34. 34 Seidah, N.G., Awan, Z., Chrétien, M., Mbikay, M., PCSK9: a key modulator of cardiovascular health. Circ Res 114 (2014), 1022–1036.
35. 35 Cohen, J.C., Boerwinkle, E., Mosley, T.H. Jr., Hobbs, H.H., Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 354 (2006), 1264–1272.
36. 36 Zhao, Z., Tuakli-Wosornu, Y., Lagace, T.A., et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet 79 (2006), 514–523.
37. 37 Rashid, S., Curtis, D.E., Garuti, R., et al. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci U S A 102 (2005), 5374–5379.
38. 38 Awan, Z., Baass, A., Genest, J., Proprotein convertase subtilisin/kexin type 9 (PCSK9): lessons learned from patients with hypercholesterolemia. Clin Chem 60 (2014), 1380–1389.
39. 39 Giugliano, R.P., Sabatine, M.S., Are PCSK9 inhibitors the next breakthrough in the cardiovascular field?. J Am Coll Cardiol 65 (2015), 2638–2651.
40. 40 Robinson, J.G., Farnier, M., Krempf, M., et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 372 (2015), 1489–1499.
41. 41 Sabatine, M.S., Giugliano, R.P., Wiviott, S.D., et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 372 (2015), 1500–1509.
42. 42 Ballantyne, C.M., Neutel, J., Cropp, A., et al. Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia. Am J Cardiol 115 (2015), 1212–1221.
43. 43 Swiger, K.J., Martin, S.S., PCSK9 inhibitors and neurocognitive adverse events: exploring the FDA directive and a proposal for N-of-1 trials. Drug Safety 38 (2015), 519–526.
44. 44 ClinicalTrials.gov. Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects (EBBINGHAUS). NLM Identifier: NCT02207634. Available at http://clinicaltrials.gov/show/NCT02207634. Accessed March 9, 2016.
45. 45 Fitzgerald, K., Frank-Kamenetsky, M., Shulga-Morskaya, S., et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet 383 (2014), 60–68.
46. 46 Mancini, G.B., Baker, S., Bergeron, J., et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Consensus Working Group update (2016). Can J Cardiol 32:7 Suppl (2016), S35–S65.
47. 47 Nissen, S.E., Stroes, E., Dent-Acosta, R.E., et al. GAUSS-3 Investigators. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 Randomized clinical trial. JAMA 315 (2016), 1580–1590.